fibrinolytic agents

Summary

Summary: Fibrinolysin or agents that convert plasminogen to fibrinolysin (PLASMIN).

Top Publications

  1. ncbi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
  2. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    Stroke 38:1655-711. 2007
  3. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
  4. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
  5. ncbi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
    W Hacke
    Department of Neurology, University of Heidelberg, Germany
    Lancet 352:1245-51. 1998
  6. ncbi Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
  7. ncbi Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    Dagmar Kubitza
    Bayer HealthCare AG, Institute of Clinical Pharmocology, D 42096 Wuppertal, Germany
    Clin Pharmacol Ther 78:412-21. 2005
  8. pmc Endovascular therapy after intravenous t-PA versus t-PA alone for stroke
    Joseph P Broderick
    Department of Neurology, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center, Cincinnati, OH 45267 0525, USA
    N Engl J Med 368:893-903. 2013
  9. ncbi Efficacy and safety of recombinant human activated protein C for severe sepsis
    G R Bernard
    Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    N Engl J Med 344:699-709. 2001
  10. ncbi Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    Michael Rud Lassen
    Department of Orthopaedics, Spine Clinic, Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    Lancet 375:807-15. 2010

Detail Information

Publications272 found, 100 shown here

  1. ncbi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
    ..We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke...
  2. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    Stroke 38:1655-711. 2007
    ..The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included...
  3. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
    ..We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis...
  4. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
    ..Under European Union regulations, SITS-MOST was required to assess the safety profile of alteplase in clinical practice by comparison with results in randomised controlled trials...
  5. ncbi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
    W Hacke
    Department of Neurology, University of Heidelberg, Germany
    Lancet 352:1245-51. 1998
    ..We have assessed the safety and efficacy of intravenous thrombolysis with alteplase (0.9 mg/kg bodyweight) within 6 h of stroke onset...
  6. ncbi Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
    ..Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin...
  7. ncbi Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    Dagmar Kubitza
    Bayer HealthCare AG, Institute of Clinical Pharmocology, D 42096 Wuppertal, Germany
    Clin Pharmacol Ther 78:412-21. 2005
    ..The aim of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 59--7939, an oral, direct factor Xa inhibitor...
  8. pmc Endovascular therapy after intravenous t-PA versus t-PA alone for stroke
    Joseph P Broderick
    Department of Neurology, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center, Cincinnati, OH 45267 0525, USA
    N Engl J Med 368:893-903. 2013
    ....
  9. ncbi Efficacy and safety of recombinant human activated protein C for severe sepsis
    G R Bernard
    Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    N Engl J Med 344:699-709. 2001
    ..In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis...
  10. ncbi Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    Michael Rud Lassen
    Department of Orthopaedics, Spine Clinic, Clinical Trial Unit, Hørsholm Hospital, University of Copenhagen, Hørsholm, Denmark
    Lancet 375:807-15. 2010
    ..Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement...
  11. pmc A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial
    Phillip A Scott
    Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA
    Lancet Neurol 12:139-48. 2013
    ..Several types of barrier frequently prevent its use. We assessed whether a standardised, barrier-assessment, multicomponent intervention could increase alteplase use in community hospitals in Michigan, USA...
  12. ncbi Reducing in-hospital delay to 20 minutes in stroke thrombolysis
    Atte Meretoja
    Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland
    Neurology 79:306-13. 2012
    ..Efficacy of thrombolytic therapy for ischemic stroke decreases with time elapsed from symptom onset. We analyzed the effect of interventions aimed to reduce treatment delays in our single-center observational series...
  13. ncbi Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic
    Manuel Yepes
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Neurosci 32:48-55. 2009
    ..Here, the best studied pathways of tPA neurotoxicity are discussed along with future directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stroke...
  14. ncbi Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, 10833 LeConte Ave, Los Angeles, CA 90095 1679, USA
    Circulation 123:750-8. 2011
    ..The benefits of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke are time dependent, and guidelines recommend an arrival to treatment initiation (door-to-needle) time of ≤60 minutes...
  15. ncbi Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    H Buller
    Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 6:1313-8. 2008
    ..We conducted a dose-ranging study in patients with deep vein thrombosis...
  16. ncbi Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008
    ..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or LMWH at presentation (Grade 2C)...
  17. ncbi Magnetic Resonance Imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke
    Guillaume Turc
    Service de Neurologie, Hopital Sainte Anne, 1 rue Cabanis, 75674 Paris Cedex 14, France
    Stroke 44:1323-8. 2013
    ..We adapted the score for patients undergoing MRI as the first-line diagnostic tool...
  18. ncbi Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry
    T Nezu
    Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
    Neurology 75:555-61. 2010
    ....
  19. ncbi Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 105:444-53. 2011
    ....
  20. ncbi The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation
    Vidya Perera
    Department of Aged Care and Clinical Pharmacology, Royal North Shore Hospital, St Leonards, NSW, Australia
    Age Ageing 38:156-62. 2009
    ..to investigate the impact of frailty on the utilisation of antithrombotics and on clinical outcomes in older people with atrial fibrillation (AF)...
  21. ncbi Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study
    Linda R Tulner
    Department of Geriatric Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Drugs Aging 27:39-50. 2010
    ..As a secondary objective, we wanted to establish how many patients discontinue OAC because of major bleeding...
  22. pmc Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis
    Andria L Ford
    Washington University School of Medicine, Department of Neurology, and Emergency Department, Neurology and Neursurgery Center, Barnes Jewish Hospital, 600 South Euclid Avenue, Box 8111, St Louis, MO 63110, USA
    Stroke 43:3395-8. 2012
    ..We used lean process improvement methodology to develop a streamlined intravenous tPA protocol...
  23. pmc Important determinants for fucoidan bioactivity: a critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds
    Marcel Tutor Ale
    Center for Bioprocess Engineering, Department of Chemical and Biochemical Engineering, Technical University of Denmark DTU, Søltofts Plads, Building 229, DK 2800 Kgs Lyngby, Denmark
    Mar Drugs 9:2106-30. 2011
    ....
  24. ncbi Body temperature and response to thrombolytic therapy in acute ischaemic stroke
    M Millan
    Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Eur J Neurol 15:1384-9. 2008
    ..To determine the relationship between body temperature (BT), arterial recanalization, functional outcome, and hemorrhagic transformation (HT) of cerebral infarction in patients treated with i.v. tissue plasminogen activator (tPA)...
  25. ncbi Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
    ..This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset...
  26. ncbi Structure-based design of novel potent nonpeptide thrombin inhibitors
    Norbert H Hauel
    Boehringer Ingelheim Pharma KG, Research Division, Birkendorfer Strasse 65, D 88397 Biberach Riss, Germany
    J Med Chem 45:1757-66. 2002
    ..This zwitterionic molecule was converted into the double-prodrug 31 (BIBR 1048), which showed strong oral activity in different animal species. On the basis of these results, 31 was chosen for clinical development...
  27. pmc Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis
    Maarten G Lansberg
    Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA 94304 9705, USA
    Stroke 40:2438-41. 2009
    ..The purpose of this study was to produce reliable and precise estimates of the treatment effect of tPA by pooling data from all relevant studies...
  28. ncbi Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial
    Wade S Smith
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    Stroke 39:1205-12. 2008
    ..Enhancements in embolectomy device design may improve recanalization rates...
  29. ncbi Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    P A Barber
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 56:1015-20. 2001
    ..Thrombolytic therapy for acute stroke (<3 hours) will not have a major impact on death and dependency unless it is accessible to more patients...
  30. ncbi Incidence of chronic atrial fibrillation in general practice and its treatment pattern
    Ana Ruigómez
    Centro Español de Investigación Farmacoepidemiológica CEIFE, C Almirante 28, 2 degrees, 28004, Madrid, Spain
    J Clin Epidemiol 55:358-63. 2002
    ..Less than half of patients with chronic AF and no contraindications for anticoagulation received warfarin within the first trimester after the diagnosis...
  31. pmc Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study
    Werner Hacke
    Department of Neurology, University of Heidelberg, Heidelberg, Germany
    Lancet Neurol 8:141-50. 2009
    ....
  32. ncbi Safety and outcome after thrombolysis in stroke patients with mild symptoms
    M Kohrmann
    Department of Neurology, University of Erlangen, Schwabachanlage 6, Erlangen, Germany
    Cerebrovasc Dis 27:160-6. 2009
    ..We aimed to assess the safety and outcome of thrombolysis therapy in patients with minor but disabling stroke symptoms...
  33. ncbi Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications
    Roberto J C Fonseca
    Universidade Federal do Rio de Janeiro, Caixa Postal 68041, Rio de Janeiro, RJ, 21941 590, Brazil
    Thromb Haemost 102:829-36. 2009
    ..In conclusion, the location of 2,4-disulfated fucose units in the polysaccharide chains dictates the effects on coagulation, thrombosis and bleeding...
  34. ncbi Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands--The EXAMINE-AF study. A questionnaire survey
    T Dinh
    Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Clin Pract 61:24-31. 2007
    ..Factors for oral anticoagulation prescription are heart failure, physician specialty and contraindications. Availability of guidelines seems instrumental for application of appropriate antithrombotic treatment...
  35. ncbi Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update
    L Derex
    Service d Urgences Neurovasculaires, Hopital Neurologique, Lyon, France
    J Neurol Neurosurg Psychiatry 79:1093-9. 2008
    ..The input of multimodal MRI and biological predictors of ICH deserves further investigation...
  36. ncbi Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group
    D Woo
    Department of Neurology, University of Cincinnati, Cincinnati, Ohio 45220, USA
    Stroke 30:2355-9. 1999
    ..Of 42 possible points, 7 points are directly related to measurement of language compared with only 2 points related to neglect...
  37. ncbi Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Hans Christoph Diener
    Department of Neurology, University Hospital Essen, Essen, Germany
    Lancet Neurol 9:1157-63. 2010
    ..We aimed to assess the effects of dabigatran compared with warfarin in the subgroup of patients with previous stroke or transient ischaemic attack...
  38. ncbi Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles
    Tze Wen Chung
    Department of Chemical Engineering, National Yunlin University of Science and Technology, Tou Liu, Yunlin, Taiwan, ROC
    Biomaterials 29:228-37. 2008
    ..In conclusion, the NPs designed based on new concepts significantly accelerate thrombolysis in vitro in this model, and may be useful in clinical study...
  39. ncbi Routine early angioplasty after fibrinolysis for acute myocardial infarction
    Warren J Cantor
    Southlake Regional Health Centre, Newmarket, ON, Canada
    N Engl J Med 360:2705-18. 2009
    ..The role and optimal timing of routine PCI after fibrinolysis have not been established...
  40. ncbi Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
    ..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)...
  41. ncbi Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
    Robby Nieuwlaat
    Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
    Eur Heart J 27:3018-26. 2006
    ....
  42. ncbi The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke
    David M Kent
    Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Stroke 37:2957-62. 2006
    ..Therefore, we aimed to develop a Stroke-Thrombolytic Predictive Instrument (TPI) to aid physicians considering thrombolysis for stroke...
  43. ncbi Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR
    Niaz Ahmed
    Department of Neurology, Karolinska University Hospital, and Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden
    Lancet Neurol 9:866-74. 2010
    ..5 h after stroke onset. We aimed to assess the implementation of the wider time window, its effect on the admission-to-treatment time, and safety and functional outcome in patients recorded in SITS-ISTR...
  44. ncbi Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point
    Gjin Ndrepepa
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    J Am Coll Cardiol 51:690-7. 2008
    ....
  45. ncbi Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
    Donald J P Pinto
    Discovery Chemistry, Research and Development, Bristol Myers Squibb Company, 31 Pennington Rocky Hill Road, Pennington, New Jersey 08534, USA
    J Med Chem 50:5339-56. 2007
    ..Compound 40 exhibits a high degree of fXa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to 4...
  46. ncbi Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial
    Frederick Feit
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Am J Cardiol 100:1364-9. 2007
    ..A number of baseline and periprocedural factors independently predicted major hemorrhage, including treatment with heparin plus GPI...
  47. ncbi Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study
    Mikael Mazighi
    Department of Neurology and Stroke Centre, Bichat University Hospital, Paris, France Diderot University, Paris, France
    Lancet Neurol 8:802-9. 2009
    ..The aim of this study was to ascertain the effect of a combined IV-endovascular approach (intra-arterial alteplase and, if required, additional thrombectomy) in patients with stroke due to arterial occlusion...
  48. ncbi STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
    Gilles Montalescot
    Institut de Cardiologie and INSERM U856, Pitie Salpetriere University Hospital, AP HP, 47 Boulevard de l Hopital, Paris 75013, France
    Eur Heart J 28:1409-17. 2007
    ..The aim of this study was to describe the management and outcomes using 'real-world' data taking the new definition of acute myocardial infarction into account...
  49. ncbi Stroke research priorities for the next decade--A representative view of the European scientific community
    Stephen Meairs
    Neurologische Klinik, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer, DE 68135 Mannheim Germany
    Cerebrovasc Dis 22:75-82. 2006
  50. ncbi PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism
    G J del Zoppo
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, Scripps Clinic and Research Foundation, La Jolla, Calif 92037, USA
    Stroke 29:4-11. 1998
    ....
  51. ncbi Facilitated PCI in patients with ST-elevation myocardial infarction
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, F25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    N Engl J Med 358:2205-17. 2008
    ....
  52. ncbi Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors
    Maarten G Lansberg
    Stanford University, Stanford Stroke Center, Palo Alto, CA 94304, USA
    Cerebrovasc Dis 24:1-10. 2007
    ....
  53. ncbi Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007
  54. pmc Methodology of the Interventional Management of Stroke III Trial
    Pooja Khatri
    Department of Neurology, University of Cincinnati, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267 0525, USA
    Int J Stroke 3:130-7. 2008
    ..a.) approach to recanalization may be more effective than standard i.v. rt-PA (Activase) alone for moderate-to-large National Institutes of Health Stroke Scale (NIHSS>or=10) strokes, and with a similar safety profile...
  55. ncbi In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor
    E Perzborn
    Cardiovascular Research, Bayer HealthCare AG, Wuppertal, Germany
    J Thromb Haemost 3:514-21. 2005
    ..Bleeding times in rats and rabbits were not significantly affected at antithrombotic doses (3 mg kg(-1) p.o., AV shunt). Based on these results, BAY 59-7939 was selected for clinical development...
  56. ncbi Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
    Hans Christoph Diener
    Department of Neurology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
    Lancet Neurol 11:225-31. 2012
    ....
  57. pmc Impact of acute ischemic stroke treatment in patients >80 years of age: the specialized program of translational research in acute stroke (SPOTRIAS) consortium experience
    Joshua Z Willey
    Department of Neurology, 710 West 168 Street, Box 30, New York, NY 10032, USA
    Stroke 43:2369-75. 2012
    ....
  58. ncbi Intraoperative thrombolysis in a patient with cardiopulmonary arrest undergoing caesarean delivery
    M Wenk
    Department of Anesthesiology and Intensive Care, St Franziskus Hospital Muenster, Muenster, Germany
    Anaesth Intensive Care 39:671-4. 2011
    ..The patient survived and was later discharged without any major neurological deficit...
  59. ncbi Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies
    Caroline E Lovelock
    Stroke Prevention Research Unit, University Department of Clinical Neurology, Level 6, West Wing, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU
    Stroke 41:1222-8. 2010
    ..Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA)...
  60. ncbi Thrombolysis targeting MRI defined tissue at risk in minor stroke
    A Kruetzelmann
    Neuro Zentrum, Klinik und Poliklinik fur Neurologie, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    J Neurol Neurosurg Psychiatry 80:1156-8. 2009
    ..Treatment with intravenous tissue plasminogen activator (IV-tPA) is usually not recommended in patients with minor stroke. Clinical and imaging outcome were studied after IV-tPA treatment based on MRI criteria in patients with minor stroke...
  61. ncbi Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
    A Furlan
    Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 282:2003-11. 1999
    ..Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed...
  62. ncbi Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an obs
    Niaz Ahmed
    Department of Clinical Neurosciences, Karolinska Institutet
    JAMA Neurol 70:837-44. 2013
    ..Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no statistically significant benefit beyond 4.5 hours, with the possible advantage perhaps offset by risk...
  63. ncbi Intravenous alteplase for stroke in those older than 80 years old
    Gary A Ford
    Department of Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
    Stroke 41:2568-74. 2010
    ..We examined outcomes and symptomatic intracerebral hemorrhage rates in ≤ 80- and > 80-year-old patients in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register...
  64. ncbi Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis
    Ricarda Marinigh
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Am Coll Cardiol 56:827-37. 2010
    ..Therefore, age alone should not prevent prescription of OAC in elderly patients, given an appropriate stroke and bleeding risk stratification...
  65. ncbi Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  66. ncbi Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry
    Julia Ferrari
    Department of Neurology, Hospital Barmherzige Brueder, Vienna, Austria
    Stroke 41:2001-4. 2010
    ..Previous small-scale studies suggested that the earlier patients arrive, the longer it takes to administer recombinant tissue plasminogen activator...
  67. pmc Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence
    Denis Vivien
    Inserm UMR S 919, Serine Proteases and Pathophysiology of the Neurovascular Unit, GIP Cyceron, Universite de Caen Basse Normandie, Caen Cedex, France
    J Cereb Blood Flow Metab 31:2119-34. 2011
    ..The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke...
  68. ncbi Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy
    Menko Jan de Boer
    Department of Cardiology, Isala Klinieken lokatie de Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands
    J Am Coll Cardiol 39:1723-8. 2002
    ..This study sought to determine the short- and long-term outcome of primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) in patients older than 75 years of age...
  69. ncbi Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate preho
    Holger Thiele
    Department of Internal Medicine Cardiology, University of Leipzig Heart Center, Leipzig, Germany
    JACC Cardiovasc Interv 4:605-14. 2011
    ....
  70. ncbi Intravenous thrombolysis for stroke increases over time at primary stroke centers
    Shyam Prabhakaran
    Rush University Medical Center, Department of Neurological Sciences, Chicago, Illinois, USA
    Stroke 43:875-7. 2012
    ..We evaluated the impact that duration as a primary stroke center (PSC) had on tissue-type plasminogen activator (tPA) utilization for acute ischemic stroke...
  71. ncbi The response to IV rt-PA in very old stroke patients
    M Gomez-Choco
    Stroke Unit, Institute of Neurosciences, Hospital Clinic, Barcelona, Spain
    Eur J Neurol 15:253-6. 2008
    ..The rates of clinical improvement, mortality, or symptomatic CNS bleeding were also unrelated to age and sex. In conclusion, the response to IV rtPA is not impaired in elderly stroke patients and male and female are equally responsive...
  72. ncbi Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
    ..The intention is to also seek approval of this definition from the regulatory authorities...
  73. ncbi Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Theodore E Warkentin
    Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, 237 Barton Street E, Hamilton, Ontario, Canada
    Chest 133:340S-380S. 2008
    ..For patients receiving VKAs at the time of diagnosis of HIT, we recommend use of vitamin K (10 mg po or 5 to 10 mg IV) [Grade 1C]...
  74. ncbi Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke
    Svetlna Pundik
    The Neurological Institute of University Hospitals of Cleveland, Case Medical Center, Cleveland, Ohio, USA
    J Stroke Cerebrovasc Dis 17:266-72. 2008
    ..However, it is unclear whether age over 80 years is a predictor for hemorrhagic transformation after intravenous, intra-arterial, or a combination of both thrombolytic therapies...
  75. pmc Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia
    Wenlan Liu
    College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    Stroke 40:2526-31. 2009
    ..Therefore, we hypothesized that normobaric hyperoxia could increase the safety of delayed tPA thrombolysis in stroke...
  76. ncbi Fibrin(ogen)olytic activity of bumblebee venom serine protease
    Yuling Qiu
    College of Natural Resources and Life Science, Dong A University, Busan 604 714, Republic of Korea
    Toxicol Appl Pharmacol 255:207-13. 2011
    ..These findings offer significant insight into the allergic reaction sequence that is initiated by bee venom serine protease and its potential usefulness as a clinical agent in the field of hemostasis and thrombosis...
  77. ncbi Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
    ..We compared traditional heparin treatment with intravenous enoxaparin in primary PCI...
  78. ncbi Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 31:3034-40. 2000
    ....
  79. pmc Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive
    Nishant K Mishra
    Acute Stroke Unit, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow G11 6NT, UK
    BMJ 341:c6046. 2010
    ..To assess effect of age on response to alteplase in acute ischaemic stroke...
  80. ncbi Stroke epidemiology, patterns of management, and outcomes in Fortaleza, Brazil: a hospital-based multicenter prospective study
    João José Freitas de Carvalho
    Hospital Geral de Fortaleza, Fortaleza, Brazil
    Stroke 42:3341-6. 2011
    ..Our objective was to describe the frequency of risk factors, patterns of management, and outcome of patients admitted with stroke in Fortaleza, the fifth largest city in Brazil...
  81. ncbi Antiplatelet, anticoagulant, and fibrinolytic activity in vitro of extracts from selected fruits and vegetables
    Constanza Torres-Urrutia
    Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, Talca, Chile
    Blood Coagul Fibrinolysis 22:197-205. 2011
    ..Further investigations are necessary to advance in knowledge of the active compounds of these fruits and vegetables and their mechanisms of action...
  82. pmc Intravenous tissue plasminogen activator and stroke in the elderly
    W T Longstreth
    Department of Neurology, University of Washington, Seattle, 98195, USA
    Am J Emerg Med 28:359-63. 2010
    ....
  83. ncbi Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study
    C D Jensen
    Wansbeck General Hospital, Woodhorn Lane, Ashington, Northumberland NE63 9JJ, UK
    J Bone Joint Surg Br 93:91-5. 2011
    ....
  84. ncbi Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis
    Yasuharu Tokuda
    Department of Medicine, Okinawa Chubu Hospital, Okinawa, Japan
    Chest 129:783-90. 2006
    ..Randomized controlled trials have shown conflicting findings about the role of intrapleural fibrinolytic therapy for the treatment of empyema and complicated parapneumonic effusions in adult patients...
  85. ncbi A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)
    Henry Ma
    National Stroke Research Institute, Florey Neuroscience Institutes, Austin Health, University of Melbourne, Heidelberg Heights, Victoria, Australia
    Int J Stroke 7:74-80. 2012
    ....
  86. ncbi Improving stroke risk stratification in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    Am J Med 123:484-8. 2010
    ..This would simplify our approach to thromboprophylaxis in patients with atrial fibrillation...
  87. ncbi Indications for thrombolysis in deep venous thrombosis
    P Gogalniceanu
    St George s Regional Vascular Institute, 4th Floor, St James Wing, St George s Hospital NHS Trust, Tooting, London SW17 0QT, United Kingdom
    Eur J Vasc Endovasc Surg 38:192-8. 2009
    ..Catheter directed thrombolysis (CDT) is an alternative method for treating DVTs but there is no consensus regarding indications for its use...
  88. ncbi A graphic reanalysis of the NINDS Trial
    Jerome R Hoffman
    Department of Emergency Medicine, University of California School of Medicine, Los Angeles, CA, USA
    Ann Emerg Med 54:329-36, 336.e1-35. 2009
    ..The initial report of the National Institute of Neurologic Diseases and Stroke (NINDS) trials of tissue plasminogen activator in acute ischemic stroke is an example of this phenomenon...
  89. pmc Purification and characterization of a fibrinolytic enzyme produced from Bacillus sp. strain CK 11-4 screened from Chungkook-Jang
    W Kim
    Department of Biotechnology, Institute of R and D, Yangpyung Dong, Youngdeungpo gu, Seoul, South Korea
    Appl Environ Microbiol 62:2482-8. 1996
    ..A similar result was also obtained from fibrin plate analysis...
  90. ncbi Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Clive Kearon
    Hamilton Health Sciences, Henderson Division, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:454S-545S. 2008
    ..For extensive superficial vein thrombosis, we recommend treatment with prophylactic or intermediate doses of LMWH or intermediate doses of UFH for 4 weeks (Grade 1B)...
  91. pmc Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation
    P Gresele
    Institute of Internal and Vascular Medicine, University of Perugia, 06126 Perugia, Italy
    J Clin Invest 101:667-76. 1998
    ....
  92. ncbi Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome managemen
    X Q Zhao
    University of Washington School of Medicine, Seattle, Washington, USA
    Circulation 100:1609-15. 1999
    ....
  93. ncbi Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years
    D Kim
    University of California at Los Angeles Stroke Center, Department of Neurology, UCLA Medical Center, Los Angeles, CA, USA
    AJNR Am J Neuroradiol 28:159-63. 2007
    ..The purpose of this study was to compare the baseline characteristics, complications, and outcomes between intra-arterially treated ischemic stroke patients aged > or = 80 years and their younger counterparts...
  94. ncbi Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
    Joan Montaner
    Cerebrovascular Unit, Vall d Hebron Hospital, Barcelona, Spain
    Circulation 107:598-603. 2003
    ..We aimed to correlate plasmatic MMP levels with the appearance of intracranial bleeding complications in stroke patients treated with t-PA...
  95. ncbi Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation
    A Tateishi
    Departments of Gastroenterology, Radiology and Surgical Oncology, University of Tokyo, Tokyo, Japan
    J Gastroenterol Hepatol 16:1429-33. 2001
    ..The only risk factor of thrombosis that was detected was decreased protein S activity...
  96. pmc Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older
    Farrah J Mateen
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:334-8. 2009
    ..Most patients aged 90 years or older who received intravenous tPA for acute ischemic stroke had poor 30-day functional outcomes or died. Intravenous tPA treatment in this age group does not improve the outcome of ischemic stroke...
  97. ncbi Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis
    Perttu J Lindsberg
    Department of Neurology, Neurosciences Program, Biomedicum Helsinki, Helsinki, Finland
    Stroke 37:922-8. 2006
    ....
  98. ncbi Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits
    Pancras C Wong
    Cardiovascular Biology, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Pharmacol Exp Ther 303:993-1000. 2002
    ..Therefore, these results suggest that DPC423 is a clinically useful oral anticoagulant for the prevention of arterial thrombosis...
  99. ncbi Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, Department of Medicine, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada
    Expert Opin Pharmacother 5:1373-84. 2004
    ..5 mg once-daily s.c. has been approved for the prevention of venous thromboembolism after major orthopaedic surgery. Fondaparinux use in extended prophylaxis (4 weeks) after hip fracture surgery has also been recently approved...
  100. ncbi Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics
    P C Wong
    Cardiovascular Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE 19880 0400, USA
    J Pharmacol Exp Ther 292:351-7. 2000
    ..7 h. Therefore, our study suggests that SF303, SK549, and their analogs represent a new class of synthetic fXa inhibitors that may be clinically useful as antithrombotic agents...
  101. ncbi Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis
    J M Wardlaw
    Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Stroke 34:1437-42. 2003
    ..Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely used in clinical practice as it could be. Have new data since 1995 strengthened the evidence sufficiently to justify more widespread use of rtPA?..

Research Grants64

  1. Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
    Carl W White; Fiscal Year: 2013
    ..Effective anticoagulant and/or fibrinolytic agents will be cross-checked to verify lack of exacerbation of skin injuries...
  2. Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial
    Anil Sapru; Fiscal Year: 2013
    ..insights into the effect of TGC-NL on clinical outcome and could lead to the use of anti-coagulant or pro fibrinolytic agents as adjunctive therapies among select groups of critically ill children with hyperglycemia who may not be ..
  3. Therapeutic thrombin analogs
    ERIK IAN TUCKER; Fiscal Year: 2011
    ....
  4. Image-Guided Non-Invasive Ultrasonic Thrombolysis Using Histotripsy
    Zhen Xu; Fiscal Year: 2012
    ....
  5. Sonolysis in Acute Coronary Syndromes
    Feng Xie; Fiscal Year: 2012
    ..Clinical methods currently utilized to treat this are fibrinolytic agents or percutaneous coronary interventions, combined with anti-platelet agents...
  6. PROTEINASE IN FIBRINOLYSIS AND THROMBOLYTIC THERAPY
    STEVEN GONIAS; Fiscal Year: 1993
    ..During the next five years, the applicant and the institution share the objective of developing this laboratory into a well established center for hemostasis research in this country...
  7. Bead-Based Approach for Combined Mechanical and Pharmacological Treatment of Acut
    Keith B Neeves; Fiscal Year: 2013
    ..blood and, upon application of a magnetic field, self-assemble into small microdevices capable of targeting fibrinolytic agents and mechanically attacking a clot in the absence of catheters...
  8. ENHANCING THROMBOLYSIS BY INHIBITION OF A2-ANTIPLASMIN
    Guy Reed; Fiscal Year: 1993
    ..is a molecular biologist with unique experience in the design and expression of recombinant, hybrid fibrinolytic agents. Dr...
  9. Comparative Effectiveness of Medications Used in Congenital Heart Surgery
    JENNIFER S contact LI; Fiscal Year: 2010
    ..This application will focus on investigating medications in 3 therapeutic areas: anti-fibrinolytic agents used during surgery, afterload reduction in the post-operative setting, and peri-operative antibiotic ..
  10. TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL CELL FUNCTIONS
    CORA JEAN EDGELL; Fiscal Year: 1991
    ..thrombogenic agents like von Willebrand factor, but also antithrombogenic agents like antithrombin III, and fibrinolytic agents like tissue plasminogen activator...
  11. IN VIVO EVALUATION OF ULTRASOUND ENHANCED LYSIS
    DOUGLAS HANSMANN; Fiscal Year: 1999
    ..3. Conduct a 10-patient pilot trial of peripheral arterial thrombolysis using the EKOS device and use the results to plan and initiate a prospective, multi-center study of 40 patients. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  12. Production of human CD39 as an antithrombotic agent
    SOONSEOG JEONG; Fiscal Year: 2004
    ..Many of the current anti-platelet or fibrinolytic agents are undesirable due to the lack of specificity, narrow time window of administration, or severe adverse ..
  13. STROKE MONITORING WITH DENSE-ARRAY EEG
    Phan Luu; Fiscal Year: 2000
    ..abstract_text> ..
  14. Interventional Management of Stroke III Planning Grant
    Joseph Broderick; Fiscal Year: 2004
    ..10. Explore funding of interventional angiography by CMS. 11. Continue interaction with industry, with attention to devices that might be applied to a device-augmented future IV/IA paradigm. ..
  15. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2003
    ..abstract_text> ..
  16. Familial Intracranial Aneurysm Study II (FIA II)
    JOSEPH PAUL BRODERICK; Fiscal Year: 2010
    ..Finally, we will use bioinformatics, statistical methods, and gene sequencing, to identify specific disease producing mutations and/or high risk haplotypes whose functional relevance will be subsequently explored. ..
  17. Plasminogen activators and cerebral ischemic injury
    William M Armstead; Fiscal Year: 2010
    ....
  18. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2005
    ..These studies may lead to therapies for brain injured children. ..
  19. Procoagulant Microparticles: Novel Determinants of Venous Thrombosis
    THOMAS WILLIAM WAKEFIELD; Fiscal Year: 2011
    ..Lay Summary: This proposal will determine the role of procoagulant elements termed microparticles in the etiology of venous thrombosis and their use as a diagnostic tool. ..
  20. Circle of Willis variability and migraine
    BRETT LEE CUCCHIARA; Fiscal Year: 2010
    ..If this hypothesis is confirmed, this could lead to new treatments based on a better understanding of migraine mechanisms and might help identify patients with migraine who are at risk of stroke. ..
  21. Prospective Investigation for Pulmonary Embolism Dx III
    Paul Stein; Fiscal Year: 2008
    ..abstract_text> ..
  22. PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DX-II
    Paul Stein; Fiscal Year: 2003
    ..4) The team of investigators is strong, and has collaborated previously in successful research in PE. ..
  23. CYTOKINE BALANCE IN VENOUS THROMBOSIS
    Thomas Wakefield; Fiscal Year: 2002
    ..abstract_text> ..
  24. MICROVASCULAR OCCLUSION IN ACUTE FOCAL CEREBRAL ISCHEMIA
    Gregory Del Zoppo; Fiscal Year: 2004
    ..These studies are a direct extension of completed work of this proposal, and are expected to add greatly to the understanding of how vascular ischemia affects neuron integrity with testable treatment strategies. ..
  25. PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DX-II
    Victor Tapson; Fiscal Year: 2003
    ..abstract_text> ..
  26. The Natural History of Venous Thromboembolism in the Elderly
    Frederick A Spencer; Fiscal Year: 2010
    ..We will also examine how elderly patients with venous thromboembolism are currently being treated, whether some patients are at risk for inappropriate or under treatment, and the relationship of treatment to future complications. ..
  27. Diffusion weighted imaging Evaluation For Understanding Stroke Evolution2:DEFUSE
    Gregory W Albers; Fiscal Year: 2010
    ..These findings will eventually lead to effective therapies for a large population of stroke patients who are currently ineligible for treatment and substantially reduce stroke-related disability. ..
  28. ECHOCARDIOGRAPHIC STROKE PREDICTORS IN A TRI-ETHNIC COMM
    Marco Di Tullio; Fiscal Year: 2003
    ..This study will be the first prospective cohort study to evaluate the role of multiple echocardiographic risk factors for ischemic stroke in a community of whites, blacks and Hispanics living in the same area. ..
  29. New MRI techniques for cerebrovascular diseases
    Gregory Albers; Fiscal Year: 2008
    ..This K24 research program will expand Dr. Albers' skills as a clinical investigator and allow him to become a more effective mentor. [unreadable] [unreadable]..
  30. Expired CO2/O2 Analysis to Diagnose Pulmonary Embolism
    JEFFREY KLINE; Fiscal Year: 2008
    ..This project will fund a clinical study designed to test the diagnostic accuracy of a hand- held breath device that detects the altered gas exchange physiology caused by PE in post-surgical and other patients at high risk for PE. ..
  31. Ischemic Stroke Treatment with Microbubbles, a Novel Clot Lysis Therapeutic
    William C Culp; Fiscal Year: 2010
    ..Our proposed pilot study will determine which of these treatments is most successful, and future studies will further explore that treatment. (End of Abstract) ..
  32. Ultrasound contrast agent enhances ultarsound assisted thrombolysis in stroke
    Azita Soltani; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  33. Surrogate markers for Severe Pulmonary Embolism
    JEFFREY KLINE; Fiscal Year: 2005
    ..This study will determine if criteria that are widely and immediately available in most hospitals can be used to risk-stratify severity of PE and to clarify the role of nonmalignant thrombophilias on the prognosis of PE. ..
  34. OU Developmental Center for Injury Prevention Research
    Gary Raskob; Fiscal Year: 2005
    ..abstract_text> ..
  35. OU Human Research Protection Program, Year 2
    Gary Raskob; Fiscal Year: 2003
    ..The University of Oklahoma is committed to maintaining these initiatives after the term of this award. ..
  36. Pretest Probability Assessment for Pulmonary Embolism
    JEFFREY KLINE; Fiscal Year: 2005
    ..In phase III, we will test the validity of the PE PREtest Consult TM and determine if the use of the PE PREtest ConsultTM will decrease unnecessary testing for PE. ..
  37. Aortic, Cardiovascular Disease and Silent Brain Infarcts
    Marco Di Tullio; Fiscal Year: 2009
    ..The present application will help fill gaps in knowledge on silent brain infarcts and their risk factors in the elderly, and identify subjects at higher risk before a symptomatic stroke or other vascular event occurs. ..
  38. Safer Antithrombotic Therapy for Elderly ACS Patients
    Eric Peterson; Fiscal Year: 2006
    ..Finally, we will use established relations with professional societies and the VHA to widely disseminate our study's major findings. ..
  39. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  40. Oxidative Mechanisms of Arsenic-induced Carcinogenesis
    Ke Liu; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  41. GENERAL CLINICAL RESEARCH CENTERS ANNUAL MEETING
    Paul Watkins; Fiscal Year: 2006
    ..abstract_text> ..
  42. SNARE PROTEINS IN PLATELET ALPHA-GRANULE SECRETION
    Robert Flaumenhaft; Fiscal Year: 2007
    ..abstract_text> ..
  43. Impact of Aging on Stroke Care: A National Perspective
    Judith Lichtman; Fiscal Year: 2004
    ..We hypothesize that variations in care exist by age. Moreover, these differences in care will not be explained by differences clinical features or co-morbid conditions associated with aging. ..
  44. MANAGEMENT OF PATIENTS WITH SUSPECTED PULMONARY EMBOLISH
    Suman Rathbun; Fiscal Year: 2005
    ..abstract_text> ..
  45. BIOSYNTHESIS OF BLOOD CLOTTING PROTEINS
    Bruce Furie; Fiscal Year: 2001
    ..Detailed knowledge of these processes will improve our understanding of the biology of these proteins and has potential for improvements in hemophilia therapy. ..
  46. INTRAVITAL VIDEO-RATE CONFOCAL MICROSCOPE
    Bruce Furie; Fiscal Year: 2001
    ..The BioRad RTS2000 real-time laser confocal system, fitted to a Nikon E600FN microscope, will provide a group of investigators with instrumentation to significantly advance their fields. ..
  47. Role of inositol trisphosphate in preconditioning
    Karin Przyklenk; Fiscal Year: 2004
    ....
  48. Angiotensin, The Vascular Endothelium, and Fibrinolysis
    DOUGLAS EUGENE VAUGHAN; Fiscal Year: 2010
    ....
  49. INTEGRATIVE PROGRAM IN CNS PATHOPHYSIOLOGY RESEARCH
    Ke Jian Liu; Fiscal Year: 2010
    ..abstract_text> ..
  50. Phase 2B Study of TNK in Acute Stroke
    E Haley; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  51. OPTIMAL PREHOSPITAL CARE OF CHILDHOOD CARDIAC ARREST
    Ian Stiell; Fiscal Year: 2004
    ..The PIs propose to conduct a large feasibility review in five urban areas and to conduct four study planning workshops. ..
  52. Optimizing Outcome After Pediatric Heart Transplantation
    Steven Webber; Fiscal Year: 2008
    ..This Pediatric CV SCCOR proposal addresses each of these areas with novel, hypothesis driven projects to rapidly and significantly advance the state-of-the-art care for pediatric heart transplant recipients. ..
  53. Factor lXa-Factor Vllla complexes in blood coagulation
    Bruce Furie; Fiscal Year: 2008
    ..abstract_text> ..
  54. STRUCTURAL STUDIES OF BLOOD CLOTTING PROTEINS
    JOHN WEISEL; Fiscal Year: 2008
    ..abstract_text> ..
  55. A Novel and Non-Invasive Method of Dermal Sampling
    Samir Mitragotri; Fiscal Year: 2003
    ..abstract_text> ..
  56. Chemical Genetic Analysis of Platelet Granule Secretion
    Robert Flaumenhaft; Fiscal Year: 2008
    ..Once identified, compounds will be tested in a previously established battery of platelet function tests and evaluated for antithrombotic potential in an in vivo murine model of thrombus formation. [unreadable] [unreadable] [unreadable]..
  57. CDP-choline: Mechanisms in Cerebral Ischemia
    RAO ADIBHATLA; Fiscal Year: 2006
    ..Arachidonic acid activates neutral sphingomyelinase, resulting in membrane disintegration. PCCT activity was stimulated by exogenous CDP-choline. Aim 2 will be tested in gerbil transient forebrain ischemia. ..
  58. Development of a combination therapy for the treatment of prostate cancer
    FRANCIS MARKLAND; Fiscal Year: 2007
    ..These studies will advance the clinical potential of this novel anticancer protein. [unreadable] [unreadable] [unreadable]..
  59. DECIPHER STICH
    JULIO PANZA; Fiscal Year: 2003
    ..abstract_text> ..
  60. OPTIMIZING MANAGEMENT OF TRANSIENT ISCHEMIC ATTACKS
    S Johnston; Fiscal Year: 2005
    ..This research will provide important results for clinicians and policy makers, and will foster the applicant's development as a health services researcher in cerebrovascular disease. ..
  61. Aging, Adenosine and Platelet-Mediated Thrombosis
    Karin Przyklenk; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..